文件临床肿瘤学会意见.pdfVIP

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non- Small Cell Lung Cancer Considering First-Line EGFR Tyrosine-Kinase Inhibitor Therapy The Provisional Clinical Opinion • “Based on the results of five phase III RCTs, patients with advanced non-small cell lung cancer of the lung who are being considered for first-l herapy with an EGFR TKI (patients who have not previously received chemotherapy or an EGFR TKI) shou